LENZ Therapeutics, Inc. (LENZ): Capital Expenditures
$827.0K
Year ended 2025-12-31
$511.0K
Trailing 12 months to 2026-06-30
-49.9%
3-year compound annual growth
-11.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $827.0K | +76.7% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $468.0K | n/m | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $30.0K | -99.5% | 2025-03-19, From 2023-01-01 |
| 2022-12-31 | $6.59M | +14.9% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $5.74M | +271.5% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $1.54M | n/a | 2022-03-21, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $827.0K | +76.7% |
| Alector, Inc. (ALEC) | 2025-12-31 | $41.0K | -96.7% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $410.0K | -79.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $1.36M | -72.2% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
Compare LENZ, ALEC, PTHS, RLAY side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗